inVentiv Health

Calling all clinical research personnel

Monday, October 23, 2017

The Pulse on Global Trials by Matthew Howes

In recent years, a global talent shortage has hampered strategic growth for many organizations. According to the ManPower Group, 36% of employers globally report talent shortages, the highest in seven years.

[Read More]

INC Research/inVentiv Health honored with SRCS Eagle Award

Wednesday, October 11, 2017

INC Research/inVentiv Health, the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract Commercial Organization), announced that it was awarded the 2017 Society for Clinical Research Sites (SCRS) Eagle Award in the CRO category during the SCRS Annual Global Site Solutions Summit held October 6-8 in Boca Raton, Florida. The award recognizes the CRO that best exemplifies outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession through strong site partnerships.

[Read More]

Paying attention to rare disease markets

Tuesday, September 5, 2017

The Pulse on Global Trials by Matthew Howes

The market opportunity of rare diseases is tremendous. Experts predict global sales of drugs with orphan designations will reach $176 billion by 2020. Biopharma as an industry is collectively investigating some 450 different orphan drugs, demonstrating the strategic value inherent in the category. But with over 6,000 rare diseases affecting an estimated 350 million people around the world, they have only just begun to tap the full market potential.

[Read More]

INC Research, inVentiv Health complete merger

Wednesday, August 2, 2017

INC Research Holdings, a global phase I-IV CRO, and inVentiv Health, a privately held global CRO and Contract Commercial Organization, announced the successful completion of their previously announced merger. The combination creates the only fully integrated biopharmaceutical solutions organization, including an end-to-end CRO and CCO. INC Research/inVentiv Health will continue to trade on the Nasdaq Global Select Market under the symbol “INCR.” The combined company will be known as INC Research/inVentiv Health on an interim basis until a relaunch under a new brand in 2018.

[Read More]

Attractiveness of conducting clinical trials outside the U.S.

Monday, July 24, 2017

The Pulse on Global Trials by Matthew Howes

In the last decade, the pharmaceutical industry has been expanding clinical research outside familiar territories like the U.S. and EU. Countries like Australia, China, India and Russia have become hot locations for pharma companies to conduct their research activities, and it’s no wonder why. The benefits to expanding clinical research to more countries around the globe are clear. Trials can be completed six to seven months sooner, on average, in countries like China or India, and at a fraction of the cost compared to domestic markets.

[Read More]

inVentiv, Medidata partner to expand use of patient-centered technology

Wednesday, June 28, 2017

Medidata, a global provider of cloud-based technology and data analytics for clinical research, and inVentiv Health, a biopharmaceutical professional services company,  announced a multi-year partnership to bring patient-centric technology and leading clinical trial expertise to the biopharmaceutical industry. The partnership will broaden the reach of Medidata’s electronic informed consent (eConsent) technology, Medidata Enroll, to patients, sites and biopharmaceutical clients worldwide.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]

Publication bias and clinical trial outcomes reporting

Monday, June 12, 2017

The Pulse on Global Trials by Matthew Howes

Last month, the world’s leading funders of medical research and international non-governmental organizations agreed to set forth new standards that will require all clinical trials they fund or support to be registered, and the results disclosed publicly within mandatory timeframes. The aim is to dramatically improve both the quality of therapies available to patients, as well as the quality of research that leads to new breakthrough. But the question remains: Will it be enough?

[Read More]